BackCara Therapeutics Overview

Cara Therapeutics Current Cash

Latest current cash for CARA: $20M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$19.85M
↓ 41.98% YoYΔ $-14.37M vs prior year quarter

Peer average

Loading

Cara Therapeutics Current Cash History

Loading

Cara Therapeutics vs. peers: Current Cash Comparison

Loading

Cara Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cara Therapeutics (CARA) FAQ

Cara Therapeutics (CARA) currently reports a current cash of $20M as of March 2026. That compares with $34M in the prior-year period — down 42.0% year over year. Use the charts on this page to explore Cara Therapeutics's current cash history and peer comparisons.

Cara Therapeutics's current cash decreased from $34M to $20M — a 42.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cara Therapeutics reported $20M in current cash as of March 2026. That compares with $34M in the prior-year period — down 42.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cara Therapeutics, and consider following CARA for alerts when major investors trade the stock.

Cara Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CARA with unrelated industries.